OregonTherapeutics is developing XCE853 : Disruptive targeted therapy “First in class” & “Best in class” in oncology.
XCE853 is based on an innovative and unique mechanism of action : Inhibition of protein disulfide isomerase.
OregonTherapeutics first objective is to bring XCE853 into clinical trial (phase 1) for the treatment of cancer within 2 years. Based on the scientific rationale, the priority indication is advanced pancreatic cancer.
Potential additional indications are ovarian, livers, and head & neck cancers.
Company Details
- Employees
- 1
- Founded
- -
- Address
- 3 Rue Du Colonel Moll, Paris,île De France 75017,france
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://oregon-therapeutics.com/
- Keywords
- Pharmaceuticals, Oncology, Biotechnology, Biology.
- HQ
- Paris, Île de France
Oregontherapeutics Questions
Oregontherapeutics's website is https://oregon-therapeutics.com/
Oregontherapeutics's LinkedIn profile is https://fr.linkedin.com/company/oregontherapeutics
Oregontherapeutics has
1 employees.
View email and phone details for 1
employees at Oregontherapeutics.
Oregontherapeutics's industry is
Pharmaceutical Manufacturing
Oregontherapeutics's top competitors are
Muller Medical S.a.s,
Medsenic,
Telomium,
Asfalia Biologics,
Neurophoenix,
Groupe Theos,
Honing Biosciences,
Ythera,
Scarcell Therapeutics,
Diotheris.
Oregontherapeutics's categories are Pharmaceutical Manufacturing
Oregontherapeutics's founding year is 2014
